

Serial No. 10/724,233
Atty. Docket No.: P63882US1

REMARKS

In the Office Action of October 19, 2005, the Examiner issued a Restriction Requirement where the previously filed claims 66-83 were subject to restriction after Applicants filed a continuation application on December 1, 2003. However, after Applicants' April 21, 2004 interview the Examiner, Applicants filed a Second Preliminary Amendment and canceled claims 1-83 and presented new claims 84-95 after discussion with the Examiner on May 12, 2005. A copy of the Second Preliminary Amendment and stamped postcard are attached with this response.

Applicants respectfully request that the Examiner reissue the Restriction Requirement based on the currently pending claims 84-95. If the Examiner has any questions regarding this response, the Examiner is invited to telephone Applicants' counsel at the number provided below.

Respectfully submitted,

JACOBSON HOLMAN PLLC

By



Joseph G. Contrera

Reg. No. 44,678

400 Seventh St., N.W.
Washington, D.C. 20004
(202) 638-6666

Date: November 1, 2005

JGC:gm

R:\SHARED\JGC\P63882US1- resp to restriction.wpd

JH Ref 163882US1

Today's Date July 13, 2004

Serial/Patent No. 10/774,733

Applicant, Patentee, Assignee AFNIS HOLM ET AL.

Filing Date/Patent Date DECEMBER 1, 2003

The following has been received in the U.S. Patent & Trademark Office on the date stamped hereon:

_____ pp. Specification & _____ Claims Response to Office Action
 Combined Declaration, Power of Attorney Disclosure Statement-IDS
 Preliminary Amendment (SECOND) Copies of References
 Rule 53 (b) Application Request for Refund
 Rule 53 (d)/RCE Application Request for Corrected Filing Receipt
 Claim to Priority and Certified Copy Petition for XOT
 Substitute Subsequent Declaration Notice of Appeal/Brief
 Maintenance Fee Sequence Listing
 Drawings _____ Sheets _____ Form _____ Informal Issue Fee Transmittal
 Assignment/Change of Name Other _____
 Small Entity Declaration

Check for \$ _____ JUL 13 2004

JH 11/01 DUE DATE

Person filing HB/1GC U.S. TRADEMARK OFFICE

JACOBSON HOLMAN PLLC
400 SEVENTH STREET, N.W.
WASHINGTON, D.C. 20004

DEBT AVAILABLE COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Arne HOLM et al.

Serial No.: 10/724,233

Filed: December 1, 2003

For: METHOD FOR PREPARING A
LIGAND PRESENTING ASSEMBLY
(LPA), AN LPA AND USES
THEREOF

Art Unit: 1639

Examiner: T.D. Wessendorf

Atty. Docket: P63882US1

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SECOND PRELIMINARY AMENDMENT

Sir/Madam:

Please enter the following amendments prior to
examination of the application on the merits.

Amendments to the claims can be found on page 2,
Remarks begin on page 15.

AMENDMENTS TO THE CLAIMS

This listing will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-83 (canceled).

84. (new) A method of solid phase peptide synthesis for preparing a ligand presenting assembly (LPA) for presentation of at least two identical peptide sequences having between 4 and 20 amino acids and having free C-terminal groups comprising the steps of:

a) assembling a plurality of identical, fully side-chain protected peptide sequences on a single solid phase resin support to provide a compound having the following formula:




wherein S represents the solid phase resin support, A represents a peptide sequence having between 4 and 20 naturally occurring L-amino acid residues, and a is ≥ 2 , and represents the number of fully side-chain protected peptide sequences on the resin support;

b) deprotecting any protected N-terminal amino groups while the peptide sequences are still attached to the resin support;

c) reacting the resulting compound having unprotected N-terminal amino groups in the peptide sequences with between 0.4 and 0.6 equivalents of an achiral dicarboxylic acid selected from the group consisting of: imino diacetic acid, 2-amino malonic acid, malonic acid, 3-amino glutaric acid and glutaric acid, being Fmoc, Boc or Aloc-protected on the amino or imino group, if present, thus having the following formula:



Wherein R represents a $N(X)(CH_2-)_2$, $NH(X)CH<$, $CH_2<$, $NH(X)CH(CH_2-)_2$ or $CH_2(CH_2-)_2$ group, and X represents an Fmoc, Boc or Aloc group, so that between 0.4 and 0.6 equivalents of said achiral dicarboxylic acid are added for every 1 equivalent of unprotected N-terminal amino group resulting in a compound with the following formula:



wherein b is between about 0.4a and 0.6a;

d) activating the product of step (c) (Formula III) so that the free carboxylic acid group reacts with the free N-terminal amino group; resulting in a compound of the following formula:



and


- e) optionally splitting of any N-terminal Fmoc-group, Boc-group or Aloc-group;
- f) cleaving the product of step (e) from the resin support resulting in a LPA peptide sequence having the following formula:



Wherein, if N is present in R, X represents H, an Fmoc, Boc or Alloc group, and Y is OH or NH₂.

85. A method according to claim 84 further comprising the steps of prior to step (f)

(e') splitting of any N-terminal Fmoc, Boc or Aloc group originating from the dicarboxylic acid used in step (c) and (e'') continuing the solid phase synthesis so as to provide a compound of the following formula:



Wherein B represents a peptide sequence, and R' represents a $\text{N}(\text{CH}_2-)_2$, $\text{NHCH}<$, or $\text{NHCH}(\text{CH}_2-)_2$ group.

86. The method according to claim 84, wherein the achiral acid is imino diacetic acid.

87. The method according to claim 84, wherein the peptide sequences are derived from OspC protein of *Borrelia burgdorferi*.

88. The method according to claim 84 for preparing an LPA for presenting two identical C-terminal sequences Pro-Lys-Lys-Pro (Seq. ID 7) of OspC.

89. The method according to claim 84, wherein the peptide sequences are derived from the flagellum of *Borrelia burgdorferi*.

90. The method according to claim 84 for preparing an LPA selected from the group consisting of

[LPA-I]: $\text{FmocN}(\text{CH}_2\text{CO-}\text{ProValValAlaGluSerProLysLysPro-OH})_2$
 $(\text{FmocN}(\text{CH}_2\text{CO-Seq. ID 1-OH})_2)$

[LPA-III]: $\text{NH}_2\text{CH}(\text{CH}_2\text{CO-}\text{ProValValAlaGluSerProLysLysPro-OH})_2$
 $(\text{NH}_2\text{CH}(\text{CH}_2\text{CO-Seq. ID 1-OH})_2)$

[LPA-VII]: $\text{CH}_2(\text{CH}_2\text{CO}-\beta\text{-Ala}-\beta\text{-AlaLysGluProAsnLysGlyValAsnProAspGluVal}\beta\text{-Ala})_2(\text{CH}_2(\text{CH}_2\text{CO}-\beta\text{-Ala}-\beta\text{-Ala-Seq. ID 4-}\beta\text{-Ala-OH})_2)_2$


[LPA-VIII]: $\text{H}_2\text{C}(\text{CH}_2\text{CO}-\text{LysGluProAsnLysGlyValAsnProAspGluVal}\beta\text{Ala})_2\text{COOH}(\text{H}_2\text{C}(\text{CH}_2\text{CO-Seq. ID 4-}\beta\text{-Ala})_2\text{COOH})$,

[LPA-IX]: Fmoc-NHCH(CH₂CO-AspArgValTyrIleHisProPheHisLeu-NH₂)₂ (Fmoc-NHCH(CH₂CO-Seq. ID 5-NH₂)₂),

[LPA-X]: Aloc-NHCH(CH₂CO-AspArgValTyrIleHisProPheHisLeu-NH₂)₂ (Aloc-NHCH(CH₂CO-Seq. ID 5-NH₂)₂), and

91. A method of solid phase peptide synthesis for preparing a ligand presenting assembly (LPA) for presentation of at least two identical peptide sequences from *Borrelia burgdorferi* having between 4 and 20 amino acids and having free C-terminal groups comprising the steps of:

a) assembling a plurality of identical, fully side-chain protected peptide sequences on a single solid phase resin support to provide a compound having the following formula:




wherein S represents the solid phase resin support, A represents a peptide sequence having between 4 and 20 naturally occurring L-amino acid residues, and a is ≥ 2 , and represents the number of fully side-chain protected peptide sequences on the resin support;

b) deprotecting any protected N-terminal amino groups while the peptide sequences are still attached to the resin support;

c) reacting the resulting compound having unprotected N-terminal amino groups in the peptide sequences with between 0.4 and 0.6 equivalents of an achiral dicarboxylic acid selected from the group consisting of: imino diacetic acid, 2-amino malonic acid, malonic acid, 3-amino glutaric acid and glutaric acid, being Fmoc, Boc or Aloc-protected on the amino or imino group, if present, thus having the following formula:



Wherein R represents a $N(X)(CH_2-)_2$, $NH(X)CH<$, $CH_2<$, $NH(X)CH(CH_2-)_2$ or $CH_2(CH_2-)_2$ group, and X represents an Fmoc, Boc or Aloc group, so that between 0.4 and 0.6 equivalents of said achiral dicarboxylic acid are added for every 1 equivalent of unprotected N-terminal amino group resulting in a compound with the following formula:



wherein b is between about 0.4a and 0.6a;

d) activating the product of step (c) (Formula III) so that the free carboxylic acid group reacts with the free N-

terminal amino group; resulting in a compound of the following formula:



and

e) optionally splitting of any N-terminal Fmoc-group, Boc-group or Aloc-group;

f) cleaving the product of step (e) from the resin support resulting in a LPA peptide sequence having the following formula:



Wherein, if N is present in R, X represents H, an Fmoc, Boc or Aloc group, and Y is OH or NH₂.

92. A method of solid phase peptide synthesis for preparing a ligand presenting assembly (LPA) for presentation of at least two identical peptide sequences derived from OspC protein of *Borrelia burgdorferi* having between 4 and 20 amino acids and having free C-terminal groups comprising the steps of:

a) assembling a plurality of identical, fully side-chain protected peptide sequences on a single solid phase resin support to provide a compound having the following formula:



wherein S represents the solid phase resin support, A represents a peptide sequence having between 4 and 20 naturally occurring L-amino acid residues, and a is ≥ 2 , and represents the number of fully side-chain protected peptide sequences on the resin support;

b) deprotecting any protected N-terminal amino groups while the peptide sequences are still attached to the resin support;

c) reacting the resulting compound having unprotected N-terminal amino groups in the peptide sequences with between 0.4 and 0.6 equivalents of an achiral dicarboxylic acid selected from the group consisting of: imino diacetic acid, 2-amino malonic acid, malonic acid, 3-amino glutaric acid and glutaric acid, being Fmoc, Boc or Aloc-protected on the amino or imino group, if present, thus having the following formula:



Wherein R represents a $\text{N}(\text{X})(\text{CH}_2-)_2$, $\text{NH}(\text{X})\text{CH}<$, $\text{CH}_2<$, $\text{NH}(\text{X})\text{CH}(\text{CH}_2-)_2$ or $\text{CH}_2(\text{CH}_2-)_2$ group, and X represents an Fmoc, Boc or Aloc group, so that between 0.4 and 0.6 equivalents of said achiral dicarboxylic acid are added for every 1

equivalent of unprotected N-terminal amino group resulting in a compound with the following formula:

$$[\text{H}_2\text{N}-\text{A}-\text{CO}]_{a-b}$$

> S

[HOOC-R-CO-HN-A-CO]_b, (Formula III)

wherein b is between about 0.4a and 0.6a;

d) activating the product of step (c) (Formula III) so that the free carboxylic acid group reacts with the free N-terminal amino group; resulting in a compound of the following formula:

$$\text{CO-HN-A-CO}$$

$$\text{CO}-\text{HN}-\text{A}-\text{CO} \quad , \quad (\text{Formula IV})$$

and

e) optionally splitting of any N-terminal Fmoc-group, Boc-group or Aloc-group;

f) cleaving the product of step (e) from the resin support resulting in a LPA peptide sequence having the following formula:

$$\text{CO-HN-A-CO-Y}$$

R<

CO-HN-A-CO-Y, (Formula V),

Wherein, if N is present in R, X represents H, an Fmoc, Boc or Aloc group, and Y is OH or NH₂.

93. A method of solid phase peptide synthesis for preparing a ligand presenting assembly (LPA) for presentation of at least two identical peptide sequences from the flagellum of *Borrelia burgdorferi* having between 4 and 20 amino acids and having free C-terminal groups comprising the steps of:

- a) assembling a plurality of identical, fully side-chain protected peptide sequences on a single solid phase resin support to provide a compound having the following formula:




wherein S represents the solid phase resin support, A represents a peptide sequence having between 4 and 20 naturally occurring L-amino acid residues, and a is ≥ 2 , and represents the number of fully side-chain protected peptide sequences on the resin support;

- b) deprotecting any protected N-terminal amino groups while the peptide sequences are still attached to the resin support;
- c) reacting the resulting compound having unprotected N-terminal amino groups in the peptide sequences with between 0.4 and 0.6 equivalents of an achiral dicarboxylic acid selected from the group consisting of: imino diacetic acid, 2-amino malonic acid, malonic acid, 3-amino glutaric acid and glutaric acid, being Fmoc, Boc or Aloc-protected on the

amino or imino group, if present, thus having the following formula:



Wherein R represents a $N(X)(CH_2)_2$, $NH(X)CH<$, $CH_2<$, $NH(X)CH(CH_2)_2$ or $CH_2(CH_2)_2$ group, and X represents an Fmoc, Boc or Aloc group, so that between 0.4 and 0.6 equivalents of said achiral dicarboxylic acid are added for every 1 equivalent of unprotected N-terminal amino group resulting in a compound with the following formula:



wherein b is between about 0.4a and 0.6a;


d) activating the product of step (c) (Formula III) so that the free carboxylic acid group reacts with the free N-terminal amino group; resulting in a compound of the following formula:



and

e) optionally splitting of any N-terminal Fmoc-group, Boc-group or Aloc-group;

f) cleaving the product of step (e) from the resin support resulting in a LPA peptide sequence having the following formula:



R<



Wherein, if N is present in R, X represents H, an Fmoc, Boc or Aloc group, and Y is OH or NH₂.

94. A ligand presenting assembly (LPA) having a formula selected from the group consisting of



(1) HN<



(2) H₂N-HC<



(3) H₂C<



CO-NH-A-CO-Y

(4) H₂N-CH<

CO-NH-A-CO-Y

or

CO-NH-A-CO-Y

(5) CH₂<

CO-NH-A-CO-Y

obtained by the method of claim 84, wherein A represents a peptide sequence having between 4 and 20 naturally occurring amino acid residues, and wherein Y represents OH or NH₂.

95. (new) The method according to claim 85 for preparing an LPA selected from the group consisting of

{LPA-IV] : H-Lys-NHCH(CH₂CO-ProValValAlaGluSerProLysLysPro-OH)₂

(H-Lys-HNCH(CH₂CO-Seq. ID 1-OH)₂

[LPA-XI] : Fmoc-AspProThrGlnAsnIleProProGly-NHCH(CH₂CO-AspArgValTyrIleHisProPheHisLeu-NH₂)₂ (Fmoc-Seq. ID 6-NHCH(CH₂CO-Seq. ID 5-NH₂)₂).

REMARKS

The Applicants would like to thank the Examiner for the opportunity to meet on April 21, 2004 and discuss the pending issues in this continuation application. The Applicants also appreciate the Examiner's suggested claim revisions of May 12, 2004.


The Applicants have reviewed the Examiner's suggested claim and provided a new set of claims for the Examiner to review in this second preliminary amendment. The Applicants do not believe that a Jepson style claim is appropriate for the present invention. Applicants suggest that the present invention is not merely an improvement of solid phase peptide synthesis, but a novel method for synthesizing peptides of a particular size so that they are prepared as dimers (or trimers) having free c-terminal ends. The claimed invention is of particular use in antigen presentation where the c-terminal end of the antigen must be free to activate an immune response.

Claims 66-83 are cancelled, and claims 84-97 are newly presented. Support for the new claims can be found in the specification. No new matter has been added with this amendment. It is believed that the claim language now more clearly defines the invention.


With regard to claim 84 (corresponding to previously presented claim 66), Applicants propose adding a limitation of between 4 and 20 amino acids to the peptide sequence, and that the peptides have free c-terminal ends in the preamble. Applicants also point out that we have replaced

the term "ligand" with the term "peptide sequence" to more accurately describe the invention. In step (a), Applicants have rewritten this step to more clearly show where the starting peptide sequence originates from and how it is attached to the resin. For example, the composition is described as a formula $[H_2N-A-CO]_{a-b}$ -S to more clearly denote the starting structure of the synthesis. Applicants also deleted the term 'ligand' and substituted the term 'peptide sequence' for consistency.

Additionally, Applicants have added a new step (c) which distinctly defines the amount of dicarboxylic acid needed in the synthesis to be between 0.4 and 0.6 equivalents with respect to the free N-terminal amino groups. Step (c) was also amended to include specific dicarboxylic acids of the formula $R(COOH)_2$, and more clearly defines R as being $N(X)(CH_2-)_2$, $NH(X)CH<$, $CH_2<$, $NH(X)CH(CH_2-)_2$ or $CH_2(CH_2-)_2$ group, and X represents an Fmoc, Boc or Aloc group and furthermore defines the product of the acidification as:



> S




wherein b is between about 0.4a and 0.6a.

Applicants wish to show that the two new formulas III and IV (which are merely new schematics of what was previously presented) depict the reaction as a two-step process. As the Examiner may recall during our interview, the reason this process uses only achiral amino acids

(instead of chiral as used by Lange et al.) is because of this two-step process. The first step is slow, not because of difficult reaction kinetics, but because only half an equivalent of acid is used to react, while the second step is considered faster because the sequences are aligned for the cyclization reaction (to give formula IV).

Applicants also further defined the resulting ring structure in step (c) that is formed when the dicarboxylic acid groups link with the N-terminal amino groups of the peptide sequences attached to the solid-phase synthesis resin as:




A limitation of linking via the N-terminal amino groups was added to address concerns the Examiner expressed regarding the Gilon reference.

Applicants would like to respectfully point out that after the interview, the Applicants reviewed the Gilon reference again and noticed that the diagram Applicants used in the interview was not accurate. Our depiction showed the Arg and Gly linked through a dicarboxylic acid by their side amino group and N-terminal groups respectively. This is not correct. As we have stated previously, the paper shows that Gilon does not use Gly but a modified Gly called N-(ω-amino alkylene)Gly (Page 482). Therefore the Gilon construct is not linking two amino acids with free amino groups via a dicarboxylic acid, but

instead, linking a synthetic amino acid with an alkyl linker of 2, 3 or 6 methylene units.

Applicants point out that the present invention does not contain any such modified amino acids in the peptide sequences. Nor does the present invention teach or suggest that the peptide sequences are linked via alkyl linkers. Applicants suggest that such specifically modified amino acids would not normally be encompassed by the term "peptide sequence" as understood by those of skill in the art. Additionally, as we stated at the interview, the ring structure created is not a cyclization of the peptide sequences themselves with alkyl linkers, as in Gilon, but instead, they comprise a solid phase linked to a peptide sequence, linked to the dicarboxylic acid, linked to a second peptide sequence, which is then linked back to the solid phase. In claim 84, step (c) has been written to more clearly show the "ring" structure of the invention:




Finally, claim 84 was drafted so that step e) defines an optional splitting of an N-terminal Fmoc-group, Boc-group or Aloc-group and step f) defines the cleavage step and the resultant product as:



wherein, if N is present in R, X represents H, an Fmoc, Boc or Aloc group, and Y is OH or NH₂.

Claim 85 corresponds to cancelled claim 67, however Applicants have rewritten the claim to comport with the new steps defined in claim 84 and additionally added the product as defined by:



wherein B represents a peptide sequence, and R' represents a N(CH₂-)₂, NHCH<, or NHCH(CH₂-)₂ group. Claim 86 corresponds to cancelled claim 69, claim 87-89 correspond to cancelled claims 76-78. Claims 90-93 correspond to cancelled claims 80-83, and claims 94 and 95 correspond to cancelled claims 85 and 86. Support for these new claims can be found in the specification at pages 18-26, 33-34, and 44-63.


Conclusion

Accordingly, in view of the foregoing amendments and remarks, the Examiner is respectfully requested to reconsider and to allow the present claims in order to find this application to be in allowable condition.

Respectfully submitted,

JACOBSON HOLMAN PLLC

By


Joseph G. Contrera

Reg. No. 44,628

400 Seventh Street, N.W.
Washington, D.C. 20004-2201
(202) 638-6666
Date: July 13, 2004
Atty. Docket: 162/P63882US1
HBJ/JGC